Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Expansion, in vivo–ex vivo cycling, and genetic manipulation of primary human hepatocytes

Expansion, in vivo–ex vivo cycling, and genetic manipulation of primary human hepatocytes

Thumbnail Image
Download
Name

1678.full.pdf

Description
Published version
Size

1.49 MB

Format

Adobe PDF

Checksum (MD5)

3eb09600506284d8d36c84fa80dbd34a

sword-2020-12-02T18:31:30.original.xml (130 B)
Original SWORD entry document
Author(s)
Michailidis, Eleftherios
•
Vercauteren, Koen
•
Mancio-Silva, Liliana
•
Andrus, Linda
•
Jahan, Cyprien
•
Ricardo-Lax, Inna
•
Zou, Chenhui
•
Kabbani, Mohammad
•
Park, Paul
•
Quirk, Corrine
more
Date Issued
2020
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
Proceedings of the National Academy of Sciences
Version
Final published version
Abstract
© 2020 National Academy of Sciences. All rights reserved. Primary human hepatocytes (PHHs) are an essential tool for modeling drug metabolism and liver disease. However, variable plating efficiencies, short lifespan in culture, and resistance to genetic manipulation have limited their use. Here, we show that the pyrrolizidine alkaloid retrorsine improves PHH repopulation of chimeric mice on average 10-fold and rescues the ability of even poorly plateable donor hepatocytes to provide cells for subsequent ex vivo cultures. These mouse-passaged (mp) PHH cultures overcome the marked donor-to-donor variability of cryopreserved PHH and remain functional for months as demonstrated by metabolic assays and infection with hepatitis B virus and Plasmodium falciparum. mpPHH can be efficiently genetically modified in culture, mobilized, and then recultured as spheroids or retransplanted to create highly humanized mice that carry a genetically altered hepatocyte graft. Together, these advances provide flexible tools for the study of human liver disease and evaluation of hepatocytetargeted gene therapy approaches.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Howard Hughes Medical Institute
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
https://hdl.handle.net/1721.1/136265
DOI of Published Version
10.1073/PNAS.1919035117
https://doi.org/10.1073/PNAS.1919035117
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.